Haemophilia A: Efanesoctocog Alfa Treatment Study

We are investigating how efanesoctocog alfa affects joint health in patients with haemophilia A. The study aims to understand improvements in joint swelling and overall health during treatment.

1-2 years 6-10 visits Monitoring phase (IV)Post-Trial Drug Access No Placebo Partially Remote Standard Medicines InjectionHematologyOrthopedics and Traumatology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Altuvoct

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Efanesoctocog Alfa

Efanesoctocog alfa is a substance that replaces missing clotting factor VIII to prevent and control bleeding in people with hemophilia A.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico

Complex Structure of Medicine Hemostasis and Thrombosis

Milan, Italy

Azienda Ospedaliera Universitaria Federico II Di Napoli

Clinical Medicine and Surgery

Piscinola, Italy

Humanitas Mirasole S.p.A.

Thrombosis and Hemorrhagic Diseases Center

Rozzano, Italy

Sponsor: Swedish Orphan Biovitrum AB (publ)

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.